ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
You play a critical role in the ABECMA treatment process, helping RRMM patients navigate their journey with ABECMA. Get information and tools you need to help support your patients below.
From the treatment process to adverse event monitoring and management information, it’s here—so you can continue to guide your patients throughout their treatment journey.
RRMM=relapsed/refractory multiple myeloma.
Treatment process includes leukapheresis, manufacturing, administration, and adverse event monitoring. A single dose of ABECMA contains a cell suspension of 300 to 460 x 106 CAR-positive T cells in one or more infusion bags.
For patients who experienced NT, including 3 patients with ongoing NT, the median duration of CAR T cell-associated NT was 6 days (range: 1 to 578 days).
During administration and at least daily for 7 days following ABECMA infusion, monitor your patients at the certified healthcare facility for adverse reactions.
to learn more about presentation, monitoring, and management of adverse events.
DOWNLOADCounsel patients and caregivers to seek immediate medical attention should signs or symptoms of CRS occur at any time
Instruct patients to remain within proximity of the certified healthcare facility for at least 4 weeks following infusion
Monitor patients for signs and symptoms of CRS
Treat at the first sign of CRS with supportive care, tocilizumab, and/or corticosteroids as needed based on the grading and management guidelines
Ensure that a minimum of 2 doses of tocilizumab per patient are available prior to infusion of ABECMA
Identify CRS based on clinical presentation. Evaluate for and treat other causes of fever, hypoxia, and hypotension
Patients who experience CRS should be closely monitored for cardiac and organ function until resolution of symptoms
Counsel patients and caregivers to seek immediate medical attention should signs or symptoms of NT occur at any time
Instruct patients to remain within proximity of the certified healthcare facility for at least 4 weeks following infusion
Monitor patients for signs and symptoms of NT
Exclude other causes of neurologic signs or symptoms
Treat promptly with supportive care and/or corticosteroids as needed based on the grading and management guidelines
150-450 x 106 CAR-positive T cells (N=127)
150-450 x 106 CAR-positive T cells (N=127)
Not resolved by month 1 following ABECMA infusion.
Warnings and precautions include:
AE=adverse event; CAR=chimeric antigen receptor; CRS=cytokine release syndrome; HLH/MAS=hemophagocytic lymphohistiocytosis/macrophage activation syndrome; NT=neurologic toxicity; REMS=Risk Evaluation and Mitigation Strategy.